IFN-β (Rebif) is a drug with valuable cancer therapeutic potential as it mediates anti-proliferation and apoptosis induction. Therefore, this study aimed to evaluate the anti-proliferation of IFN-β through assessing gene expression of p53 and caspase-3 in hepatocellular carcinoma cell (HCC) line (HepG2). The 50% inhibition viability concentration (IC50) of IFN-β was calculated by cytotoxicity assay, and it was tested on normal cell line (Vero). After treating HepG2 cells with IFN-β, p53 and caspase-3 expression was analyzed, at time intervals of 2, 4, 6, and 24 hrs, by real-time PCR, histopathology and immunohistochemistry. IC50 of IFN-β was 420 µg/ml, which wasn't cytotoxic on normal cells. P53 expression was gradually up-regulated by time, and then, it was decreased after 24 hrs incubation. However, no expression of caspase-3 was detected compared to cell control. Histopathologically, cells degeneration was remarkable after 24 hrs while no change was noticed in control. Immunohistochemical analysis revealed a decline of p53 and caspase-3 expression in treated cells with IFN-β, after 24 hrs, to 30% compared to cell control (50% and 60%, respectively). IFN-β has the potential to be utilized as a suppressor of HCC proliferation and inducer of malignant cells apoptosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.